Literature DB >> 15295340

Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicenter study.

James B Spies1, Jay M Cooper, Robert Worthington-Kirsch, John C Lipman, Benjie B Mills, James F Benenati.   

Abstract

OBJECTIVE: The purpose of this study was to estimate the outcomes of uterine embolization and hysterectomy for uterine leiomyomas. Study design This was a multicenter prospective study of patients who were treated with embolization (n=102 patients) and hysterectomy (n=50 patients) for leiomyomas. Changes in symptoms, complications, and quality of life were measured. The data analysis included linear and logistic regression, the Student t and paired t test, Fisher's exact test, and chi-squared test.
RESULTS: For patients who underwent embolization, there were marked reductions in blood loss scores (P <.001) and menorrhagia questionnaire scores (P <.001) compared with baseline. At 12 months, a larger proportion of the patients who had undergone hysterectomy experienced improved pelvic pain (P=.021). Both groups had marked improvement in other symptoms and quality of life scores, with no difference between groups. Complications were more frequent in patients who underwent hysterectomy (50% vs 27.5%; P=.01).
CONCLUSION: Both procedures substantially improved symptoms for most patients, with an advantage for hysterectomy at 12 months for pelvic pain. Serious complications were infrequent in both groups.

Entities:  

Mesh:

Year:  2004        PMID: 15295340     DOI: 10.1016/j.ajog.2004.03.037

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  17 in total

1.  Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial.

Authors:  Anu Ruuskanen; Maritta Hippeläinen; Petri Sipola; Hannu Manninen
Journal:  Eur Radiol       Date:  2010-06-06       Impact factor: 5.315

2.  Information-seeking behavior of women in their path to an innovative alternate treatment for symptomatic uterine fibroids.

Authors:  Kalyani Ankem
Journal:  J Med Libr Assoc       Date:  2007-04

Review 3.  Current evidence on uterine embolization for fibroids.

Authors:  James B Spies
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

Review 4.  Uterine anatomy and function on cine magnetic resonance imaging.

Authors:  Aki Kido; Kaori Togashi
Journal:  Reprod Med Biol       Date:  2016-02-13

Review 5.  Uterine fibroid embolization: CME update for family physicians.

Authors:  Antony Raikhlin; Mark Otto Baerlocher; Murray R Asch
Journal:  Can Fam Physician       Date:  2007-02       Impact factor: 3.275

6.  Degeneration of leiomyoma in patients referred for uterine fibroid embolization: incidence, imaging features and clinical characteristics.

Authors:  Seung Chul Han; Man-Deuk Kim; Dae Chul Jung; Myungsu Lee; Mu Sook Lee; Sung Il Park; Jong Yun Won; Do Yun Lee; Kwang Hun Lee
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

7.  The effect of uterine fibroid embolization on lower urinary tract symptoms.

Authors:  David Shveiky; Cheryl B Iglesia; Danielle D Antosh; Bela I Kudish; Joanna Peterson; Chun-Chih Huang; Chun-Chin Huang; James B Spies
Journal:  Int Urogynecol J       Date:  2012-12-18       Impact factor: 2.894

Review 8.  Image-guided thermal therapy of uterine fibroids.

Authors:  Shu-Huei Shen; Fiona Fennessy; Nathan McDannold; Ferenc Jolesz; Clare Tempany
Journal:  Semin Ultrasound CT MR       Date:  2009-04       Impact factor: 1.875

9.  Tri-acryl gelatin microsphere is better than polyvinyl alcohol in the treatment of uterine myomas with uterine artery embolization.

Authors:  Yu Gao; Fang Jiang; Xinbo Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

10.  Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids.

Authors:  Amy K O'Sullivan; David Thompson; Paula Chu; David W Lee; Elizabeth A Stewart; Milton C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  2009-01       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.